Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.

[1]  W. Ghali,et al.  Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis , 2011, Arthritis care & research.

[2]  Yasmin,et al.  Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ , 2010, European heart journal.

[3]  D. Atar,et al.  Tumor Necrosis Factor-&agr; Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies: A Controlled Study , 2010, Hypertension.

[4]  D. Symmons,et al.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[5]  P. Libby,et al.  Myeloid-Related Protein-8/14 Is Critical for the Biological Response to Vascular Injury , 2009, Circulation.

[6]  A. Ferrante,et al.  Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid arthritis , 2009, Rheumatology International.

[7]  P. Sidiropoulos,et al.  Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients , 2009, Scandinavian journal of rheumatology.

[8]  S. Oakley,et al.  Infliximab improves vascular stiffness in patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[9]  G. Baron,et al.  Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. , 2008, Rheumatology.

[10]  K. Walley,et al.  S100A8 and S100A9 Mediate Endotoxin-Induced Cardiomyocyte Dysfunction via the Receptor for Advanced Glycation End Products , 2008, Circulation research.

[11]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[12]  M. Vitale,et al.  Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. , 2007, Rheumatology.

[13]  M. Hersberger,et al.  Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. , 2007, European heart journal.

[14]  T. Tuomainen,et al.  Augmentation index and carotid intima–media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein , 2007, Journal of hypertension.

[15]  E. Vicaut,et al.  Mannheim Carotid Intima-Media Thickness Consensus (2004–2006) , 2006, Cerebrovascular Diseases.

[16]  H. Struijker‐Boudier,et al.  Expert consensus document on arterial stiffness: methodological issues and clinical applications. , 2006, European heart journal.

[17]  Michiel L Bots,et al.  Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies , 2006, Current medical research and opinion.

[18]  Yasmin,et al.  Rheumatoid Arthritis Is Associated With Increased Aortic Pulse-Wave Velocity, Which Is Reduced by Anti–Tumor Necrosis Factor-&agr; Therapy , 2006, Circulation.

[19]  J. Staessen,et al.  Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials , 2006, Stroke.

[20]  P. Libby,et al.  Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events , 2006, Circulation.

[21]  Javier Martín,et al.  Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[22]  G. McColl,et al.  Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. , 2005, Rheumatology.

[23]  D. Foell,et al.  Differential expression and response to anti‐TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis , 2005, The Journal of pathology.

[24]  James G Terry,et al.  Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors , 2005, Current controlled trials in cardiovascular medicine.

[25]  P. T. Larsson,et al.  Circulating markers of inflammation are related to carotid artery atherosclerosis. , 2005, International angiology : a journal of the International Union of Angiology.

[26]  A. Gnasso,et al.  Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. , 2004, Atherosclerosis.

[27]  M. Bots,et al.  Aortic stiffness and carotid intima‐media thickness: two independent markers of subclinical vascular damage in young adults? , 2003, European journal of clinical investigation.

[28]  R. Asmar,et al.  Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT , 2003, Blood pressure monitoring.

[29]  R. Reneman,et al.  An integrated system for the non-invasive assessment of vessel wall and hemodynamic properties of large arteries by means of ultrasound. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.

[30]  R. Jonsson,et al.  Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. , 1994, The Journal of rheumatology.

[31]  E. Lingaas,et al.  Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin , 1990, The Lancet.